Syros Pharmaceuticals (NASDAQ:SYRS) reported quarterly losses of $(0.17) per share which beat the analyst consensus estimate of $(1.35) by 87.41 percent. This is a 95.53 percent increase over losses of $(3.80) per share from the same period last year.
Northland Capital Markets Maintains Outperform on Palo Alto Networks, Raises Price Target to $585
Northland Capital Markets analyst Nehal Chokshi maintains Palo Alto Networks (NYSE:PANW) with a Outperform and raises the price target from $460 to $585.
